Keywords: s-p, boceprevir, sees, svr, weeks, drug, major

S-P's boceprevir sees 57% SVR at 28 weeks

Article | 05 May 2008

Print This

US drug major Schering-Plough presented encouraging results from a planned interim analysis of an ongoing Phase II study of boceprevir, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in